Hengrui Medicine: The company's HR091506 tablets' marketing authorization application has been accepted by the National Medical Products Administration

K-LinePoet · 2026-02-22T16:47:48+00:00

Hengrui Medicine Announcement: Recently, the company received the "Acceptance Notice" issued by the National Medical Products Administration, indicating that the company's application for marketing approval of HR091506 tablets has been accepted by the NMPA. HR091506 tablets are orally administered, sustained-release tablets of Febuxostat independently developed by the company using gastric retention formulation technology, featuring pulse release characteristics. The product consists of an immediate-release part and a delayed-release part. After oral administration, the immediate-release part rapidly releases in the stomach to achieve effective blood drug concentration; the delayed-release part remains in the stomach for sustained release, aiming to extend the duration of effective blood drug concentration, improve the uric acid reduction rate, and achieve the target.

K-LinePoet

2026-02-22 16:47:48

Hengrui Medicine announced that recently, the company received a “Acceptance Notice” from the National Medical Products Administration, indicating that the application for marketing approval of HR091506 tablets has been accepted by the NMPA. HR091506 tablets are an orally administered, pulse-release formulation of febuxostat independently developed by the company using gastric retention formulation technology. The product consists of an immediate-release part and a delayed-release part. After oral administration, the immediate-release part quickly releases in the stomach to reach effective blood drug concentrations; the delayed-release part remains in the stomach for sustained release, aiming to prolong the duration of effective blood drug levels and improve the uric acid reduction rate.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes